A multicenter, open-label study of Harvoni (sofosbuvir ledipasvir fixed dose combination) in subjects infected with chronic hepatitis C and advanced heart failure or lung disease
||Gilead Sciences, Inc
||Male and Female Patients
|U.S. Govt. ID:
||Moury Minhaz: 212-305-8056 / firstname.lastname@example.org
This research trial is being conducted to determine the safety and efficacy of HARVONI (an FDA-approved Hepatitis C Virus medication) in HCV (genotype 1, 4, 5, an 6) infected patients who also have advanced heart failure or chronic lung disease. HARVONI has not been tested in patients with HCV and heart failure or chronic lunch disease. Subjects will take HARVONI for 12 or 24 weeks, depending on the how damaged their liver is, and also if they have prior history of HCV treatment.
This study is closed
Elizabeth Verna, MD
|Have you been diagnosed with HCV?